Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/annrheumdis-2019-215960 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultrasound nail assessment in patients with psoriasic arthritis: is there an association of findings with clinical scores?
Adv Rheumatol
September 2024
Department of Internal Medicine, Hospital de Clínicas, Federal University of Paraná, Curitiba, Parana, Brazil.
Article Synopsis
- Psoriatic arthritis can affect many different parts of the body and is often linked with other issues like depression and obesity, making it hard to track patients’ health.
- The study aimed to look at specific changes in nails of people with psoriatic arthritis and see how these changes relate to different healthcare scores that measure the disease.
- Researchers examined nails from 52 patients and 50 controls using ultrasound to look for signs of disease, and their findings were assessed by a specialist.
The Effect of a Ketogenic Diet versus Mediterranean Diet on Clinical and Biochemical Markers of Inflammation in Patients with Obesity and Psoriatic Arthritis: A Randomized Crossover Trial.
Int J Mol Sci
February 2024
Second Department of Dermatology and Venereology, University of Athens Medical School, 12462 Athens, Greece.
The effect of different diet patterns on psoriasis (PSO) and psoriatic arthritis (PSA) is unknown. Τhe aim of our study was to evaluate the effectiveness of a Mediterranean diet (MD) and Ketogenic diet (KD), in patients with PSO and PSA. Twenty-six patients were randomly assigned to start either with MD or KD for a period of 8 weeks.
View Article and Find Full Text PDFReal-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice.
Reumatol Clin (Engl Ed)
January 2024
Hospital Monte Naranco, Oviedo, Spain. Electronic address:
Introduction: Apremilast is approved for treatment of psoriasis and psoriatic arthritis (PsA). Real-world evidence on apremilast effectiveness in clinical practice is limited.
Methods: Observational study enrolling adult patients, across 21 Spanish centres, who had initiated apremilast in the prior 6 (±1) months and were biologic naive.
Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study.
RMD Open
September 2023
INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Universite, Paris, France.
Objectives: We aimed to evaluate whether obese patients with psoriatic arthritis (PsA) were less likely to be in remission/low disease activity (LDA).
Methods: We used data from the ReFlaP, an international multi-centre cohort study (NCT03119805), which recruited consecutive adults with definite PsA (disease duration ≥ 2 years) from 14 countries. Demographics, clinical data, comorbidities, and patient-reported outcomes were collected.
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study.
RMD Open
April 2023
Global Medical Affairs, Novartis Pharma AG, Basel, Switzerland.
Objective: To investigate the impact of sustained low disease activity (LDA)/remission (REM) on physical function, quality of life (QoL) and structural outcomes in secukinumab-treated psoriatic arthritis (PsA) patients from the FUTURE 5 study.
Methods: FUTURE 5 was a randomised, double-blind, placebo-controlled, parallel-group, phase 3 study in patients with active PsA. Patients were categorised according to LDA (Minimal Disease Activity, MDA/Disease Activity index for Psoriatic Arthritis, DAPSA LDA+REM) or REM (very LDA/DAPSA REM): not achieving LDA/REM, achieving it once or sustained LDA/REM ≥3 times up to week 104.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!